Oral agent shows durable improvement in SUI patients

San Diego-Treatment with the dual neurotransmitter reuptake inhibitor duloxetine (Yentreve) results in durable improvement in symptoms of stress urinary incontinence, according to a study of open-label transition from placebo to active therapy.

Related Videos

Related Content

Advertisement

May 16th 2025

Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

Melissa Kaufman, MD, PhD, FACS Hannah Clarke

The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.

June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD

April 5th 2025

Vaginal prolapse repair and sling surgery significantly reduce UUI

Christina M. Mezes, DO Catherine A. Matthews, MD

"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.

April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

March 28th 2025

FDA grants marketing authorization to at-home diagnostic test for STIs

Hannah Clarke

The test can deliver diagnostic results for chlamydia, gonorrhea, and trichomoniasis.

March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.

Related Content

Advertisement

May 16th 2025

Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

Melissa Kaufman, MD, PhD, FACS Hannah Clarke

The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.

June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD

April 5th 2025

Vaginal prolapse repair and sling surgery significantly reduce UUI

Christina M. Mezes, DO Catherine A. Matthews, MD

"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.

April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

March 28th 2025

FDA grants marketing authorization to at-home diagnostic test for STIs

Hannah Clarke

The test can deliver diagnostic results for chlamydia, gonorrhea, and trichomoniasis.

March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.